Helius Medical Technologies Inc ( (HSDT) ) has released its Q2 earnings. Here is a breakdown of the information Helius Medical Technologies Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Helius Medical Technologies Inc., a Delaware-based company, operates in the medical technology sector, focusing on the development and commercialization of unique non-invasive platform technologies for neurological wellness.
In its latest earnings report for the quarter ending June 30, 2025, Helius Medical Technologies Inc. highlighted a significant increase in cash and cash equivalents, rising to $6.1 million from $1.1 million at the end of 2024, despite facing a net loss of $9.8 million for the quarter. The company also reported a decrease in total revenue to $43,000 from $182,000 in the same quarter of the previous year.
Key financial metrics revealed a gross loss of $53,000, with operating expenses slightly decreasing to $3.3 million. The company experienced a substantial non-operating income loss, primarily due to a $6.0 million change in the fair value of derivative liabilities. Despite these challenges, Helius successfully raised $9.1 million through a public offering, which contributed to its improved cash position.
Looking ahead, Helius Medical Technologies Inc. faces uncertainty regarding its ability to continue as a going concern, as it anticipates ongoing operating losses and net cash outflows until it achieves sufficient revenue levels. The company plans to fund its activities through existing cash reserves, product sales, and potential future equity or debt financing, although there is no guarantee of success in these endeavors.